Clinical Trials
68 trialsMK-4280A-007
Merck Sharp & Dohme LLC
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
MK-3475-689
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
KEYNOTE-991
Merck Sharp & Dohme LLC
KEYNOTE-937
Merck Sharp & Dohme LLC
KEYNOTE-966
Merck Sharp & Dohme LLC
KEYNOTE-966
Merck Sharp & Dohme LLC
MK-3475-775
Eisai Inc.
PEARLS
Merck Sharp & Dohme LLC
KEYNOTE-564
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-B96
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-859
Merck Sharp & Dohme LLC
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
KEYNOTE-A18
Merck Sharp & Dohme LLC
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
LEAP-007
Merck Sharp & Dohme LLC
LEAP-003
Merck Sharp & Dohme LLC
LEAP-002
Merck Sharp & Dohme LLC
LEAP-006
Merck Sharp & Dohme LLC
LEAP-011
Merck Sharp & Dohme LLC
MK-7902-017
Merck Sharp & Dohme LLC
KEYNOTE-412
Merck Sharp & Dohme LLC
KEYNOTE-826
Merck Sharp & Dohme LLC
LEAP-003
Merck Sharp & Dohme LLC
MK-3475-811
Merck Sharp & Dohme LLC
KEYNOTE-867
Merck Sharp & Dohme LLC
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
KEYVIBE-010
Merck Sharp & Dohme LLC
KEYNOTE-991
Merck Sharp & Dohme LLC
MK-3475-394
Merck Sharp & Dohme LLC
LEAP-006
Merck Sharp & Dohme LLC
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Incyte Corporation
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation
LEAP-008
Merck Sharp & Dohme LLC
MK-3475-048
Merck Sharp & Dohme LLC
KEYNOTE-641
Merck Sharp & Dohme LLC
KEYNOTE-921
Merck Sharp & Dohme LLC
KEYNOTE-913
Merck Sharp & Dohme LLC
KEYLYNK-010
Merck Sharp & Dohme LLC
LEAP-007
Merck Sharp & Dohme LLC
MK-3475-A86
Merck Sharp & Dohme LLC
KEYNOTE-716
Merck Sharp & Dohme LLC
KEYNOTE-355
Merck Sharp & Dohme LLC
KEYNOTE-590
Merck Sharp & Dohme LLC
KEYNOTE-407
Merck Sharp & Dohme LLC
KEYNOTE-177
Merck Sharp & Dohme LLC